Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
108.97
-0.23 (-0.21%)
Official Closing Price
Updated: 4:10 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
Today 13:39 EST
Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Today 12:35 EST
Via
Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Today 11:47 EST
Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.
Via
Benzinga
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Today 9:47 EST
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile.
Via
Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Today 7:16 EST
Lilly touted findings from the first head-to-head clinical trial.
Via
Investor's Business Daily
What the Options Market Tells Us About Novo Nordisk
November 29, 2024
Via
Benzinga
Is Novo Nordisk Stock a Buy?
November 29, 2024
Via
The Motley Fool
Smart Money Is Betting Big In NVO Options
November 22, 2024
Via
Benzinga
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Today 7:10 EST
Via
The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
December 03, 2024
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Via
Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
December 03, 2024
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities.
Via
Benzinga
Topics
ETFs
Technical Monday: Novo Nordisk, A Love Story
December 02, 2024
The stock has found some buyers as we begin December. Plus, holding the 23-month MA means that the company’s stock is still in a positive 2-year business cycle expansion.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Are Diet Drug Companies Over The Hump?
November 20, 2024
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation.
Via
Talk Markets
Topics
Stocks / Equities
Novo Nordisk Unusual Options Activity For November 19
November 19, 2024
Via
Benzinga
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December 02, 2024
Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.
Via
Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
December 02, 2024
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight loss programs reporting decreased use.
Via
Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
November 30, 2024
Via
The Motley Fool
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
November 29, 2024
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk.
Via
Benzinga
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
November 27, 2024
Via
The Motley Fool
Vanity Trades Moving And The Weekly Moving Average Trigger
November 26, 2024
A discussion about exponential moving average and price for our
Via
Talk Markets
Topics
Stocks / Equities
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
November 26, 2024
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.
Via
Benzinga
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
November 26, 2024
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight.
Via
Investor's Business Daily
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
November 25, 2024
Via
The Motley Fool
MDGL: A Promising Play In The Weight Loss Drug Space
November 22, 2024
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now...
Via
Talk Markets
Topics
Stocks / Equities
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
November 22, 2024
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Via
Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
November 21, 2024
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity?
Via
Benzinga
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
November 20, 2024
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing.
Via
Benzinga
Is Novo Nordisk Stock a Buy Right Now?
November 20, 2024
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Via
The Motley Fool
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
November 18, 2024
Novo Nordisk launches Wegovy in China to address rising obesity rates, priced lower than in the U.S. Initial sales start at a Shanghai public hospital.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.